A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate

American Journal of Gastroenterology

Volumn 91, Issue 3, 1996, Pages 423-433

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE;

ARTHRALGIA; BONE MARROW SUPPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEVER; GINGIVA HYPERPLASIA; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MALAISE; MEGALOCYTOSIS; MUCOSA INFLAMMATION; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; RASH; REVIEW;

6-MERCAPTOPURINE; ALGORITHMS; AZATHIOPRINE; CONTROLLED CLINICAL TRIALS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHOTREXATE;

EID: 0029923360     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
2. Weinshilboum RN, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
3. Lilleyman JS, Lennard L. Mercaptopurine metabolism and the risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343: 1188-90.
4. Lennard L, Rees CA, Lilleyman JS, et al. Childhood leukemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1983;16:359-63.
5. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia. Parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986;40:287-92.
6. Lennard L, Harrington CI, Wood M, et al. Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris. Br J Pharmacol 1987;23:229-33.
7. Van Os EC, Zins BJ, Sandborn WJ, et al. Azathioprine pharmacokinetics following intravenous, oral, delayed-release oral and rectal foam administration. Gut (in press).
8. Elion GB. The comparative metabolism of Imuran and 6-mercaptopurine in man. Proc Am Assoc Cancer Res 1969;10:21.
9. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;ii:1273-6.
10. Summers RW, Switz DN, Sessions JT, et al. National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 1979;77:847-69.
11. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: A controlled evaluation. Gastroenterology 1974;66: 916-22.
12. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisone in active Crohn's disease. Gastroenterology 1993;105:367-72.
13. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the mamagement of Crohn's disease. Gut 1995;37: 674-8.
14. Willoughby JMT, Kumar PJ, Beckett J, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;ii:944-7.
15. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
16. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;ii:955-7.
17. Rosenberg JL, Levin B, Wall AJ, et al. A controlled trial of azathioprine in Crohn's disease. Dig Dis 1975;20:721-6.
18. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Int Med 1995;122: 132-42.
19. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on a controlled therapeutic trial. Br Med J 1974;4:627-30.
20. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-9.
21. Kirk AP, Lennard-Jones JE. Controlled trial ot azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-2.
22. Caprilli R, Carratu R, Babbini M. A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in ideopathic proctocolitis. A preliminary report. Dig Dis 1975;20:115-20.
23. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992; 305:20-2.
24. Sandborn WJ, Van Os EC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109:1808-17.
25. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Int Med 1989;111:641-9.
26. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years experience. Gut 1993;34:1081-5.
27. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
28. Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992;69:1119-23.
29. Gelb A, Zalusky R. Lymphoma in Crohn's disease occurring in a patient on 6-MP. Am J Gastroenterol 1983;78:316 (letter).
30. Lemann M, Bonhomme P, Bitoun A, et al. Traitement de la maladie de Crohn par l'azathioprine ou la 6-mercaptopurine. Etude retrospective chez 126 malades. Gastroenterol Clin Biol 1990;14:548-54.
31. Larvol L, Soule JC, Tourneau AL. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994;331: 883-4.
32. Di Pavoda FE. Pharmacology of cyclosporine (Sandimmune). V. Pharmacologic effects on immune function: In vitro studies. Pharmacol Rev 1989;41:373-405.
33. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48-63.
34. Feutren G, Mihatsch MJ, Committee for the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-60.
35. Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994;330:1846-51.
36. Jewell DP, Lennard-Jones JE, and the Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease. A multicentre controlled trial. Eur J Gastroenterol Hepatol 1994;6:499-505.
37. Stange EF, Modigliani R, Penna AS, et al. European trial of cyclosporin in chronic active Crohn's disease: A 12 month study. Gastroenterology 1995;109:774-82.
38. Brynskov J, Freund L, Rasmussen SN, et al. placebo-controlled double-blind randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989;321(13)845-50.
39. Brynskov J, Freund L, Rasmussen SN, et al. Final report on a placebo-controlled, double-blind, randomized trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991;26:689-95.
40. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula in Crohn's disease. Dig Dis Sci 1994;39:374-80.
41. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with intravenous cyclosporin A. Am J Gastroenterol 1993;88:646-9.
42. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-5.
43. Kornbluth A, Lichtiger S, Present D, et al. Long-term results of oral cyclosporin in patients with severe ulcerative colitis: A double-blind, randomized, multi-center trial. Gastroenterology 1994;106:A714 (abstract).
44. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35.
45. Scalzini A, Barni C, Stellini R, et al. Fatal invasive aspergillosis during cyclosporine and steroids treatment for Crohn's disease. Dig Dis Sci 1995;40:538.
46. Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992;16:411-23.
47. Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: Pharmacology and preliminary results. Mayo Clin Proc 1996;71: 69-80.
48. Songsiridej N, Furst DE. Methotrexate: The rapidly acting drug. Bailliere's Clin Rheumatol 1990;4:575-93.
49. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991;25:306-18.
50. Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-104.
51. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Int Med 1989;110:353-6.
52. Chamiot-Prieur C, Lemann M, Mesnard B, et al. Treatment of refractory Crohn's disease (CD) with methotrexate (MTX). Gastroenterology 1993;104:A680 (abstract).
53. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851-6.
54. Arora S, Katov WN, Cooley J, et al. A double-blind randomized placebo-controlled trial of methotrexate in Crohn's disease. Gastroenterology 1992;102:A591 (abstract).
55. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
56. Kozarek RA, Patterson DJ, Gelfand MD, et al. Long-term use of methotrexate in inflammatory bowel disease: Severe disease 3, drug therapy 2. Seventh inning stretch. Gastroenterology 1992;102:A646 (abstract).
57. Kozarek RA. Review article: Immunosuppressive therapy for inflammatory bowel disease. Aliment Pharmacol Ther 1993;7:117-23.
58. Goodman TA, Polisson RP. Methotrexate: Adverse reactions and major toxicities. Rheumatic Dis Clin North Am 1994;20:513-28.
59. Roenigk HH Jr, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988;19:145-56.
60. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
61. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 1991;90:711-6.
62. Weinblatt ME. Methotrexate for chronic diseases in adults. N Engl J Med 1995;332:330-1.
63. Kozarek RA, Bredfeldt JE, Rosoff LE, et al. Does methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? Gastroenterology 1991;100:A221 (abstract).
64. Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate therapy for rheumatoid arthritis. Semin Arthritis Rheum 1991;20:317-31.
65. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexate-cyclosporine combination study group. N Engl J Med 1995;333:137-41.